

Francisco Batel-Marques

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9111437/francisco-batel-marques-publications-by-citations.pdf>
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27 papers	530 citations	13 h-index	22 g-index
27 ext. papers	651 ext. citations	3.6 avg, IF	4.21 L-index

#	Paper	IF	Citations
27	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. <i>Diabetes Research and Clinical Practice</i> , 2012 , 98, 271-84	7.4	117
26	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. <i>Breast Cancer Research</i> , 2015 , 17, 140	8.3	114
25	Number needed to treat (NNT) in clinical literature: an appraisal. <i>BMC Medicine</i> , 2017 , 15, 112	11.4	60
24	Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1431-1443	2.8	33
23	Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis. <i>European Thyroid Journal</i> , 2019 , 8, 130-143	4.2	22
22	Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis. <i>CNS Drugs</i> , 2016 , 30, 909-29	6.7	19
21	Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1259-70	2.6	19
20	Sources of information used by regulatory agencies on the generation of drug safety alerts. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 2083-94	2.8	17
19	Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012 , 17, 266-76	2.6	17
18	Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014 , 30, 729-51	2.6	15
17	Data sources on drug safety evaluation: a review of recent published meta-analyses. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 21-33	2.6	15
16	Nurses as spontaneous reporting of adverse drug reactions: expert review of routine reports. <i>Journal of Nursing Management</i> , 2014 , 22, 322-30	4.9	14
15	A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment. <i>Acta Ophthalmologica</i> , 2016 , 94, e251-9	3.7	13
14	Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis. <i>Ophthalmic Research</i> , 2017 , 57, 60-69	2.9	10
13	Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events. <i>Clinical Rheumatology</i> , 2013 , 32, 1207-14	3.9	9
12	Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1301-12	4.1	9
11	Statins and risk of cataracts: A systematic review and meta-analysis of observational studies. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e12480	3.3	7

10	Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 54-61	2.2	4
9	The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	4
8	Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 3432-3439	0.7	3
7	Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. <i>BMJ Open</i> , 2020 , 10, e041420	3	3
6	Methodologic Assessment of the Systematic Reviews of Ophthalmic Adverse Drug Reactions Published in Ophthalmology Journals: A Systematic Review. <i>Ophthalmic Research</i> , 2018 , 60, 55-68	2.9	2
5	Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , 2020 , 98, 22-31	3.7	2
4	A comparison between two recommendations to conduct and report systematic reviews on drug safety. <i>Systematic Reviews</i> , 2019 , 8, 238	3	1
3	Development of medicines consumption in Portugal before and during the financial crisis. <i>European Journal of Public Health</i> , 2021 , 31, 974-979	2.1	1
2	Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review. <i>BMJ Open</i> , 2019 , 9, e032522	3	
1	Classification of Pharmaceutical Policy Measures During the Portuguese Financial Crisis.. <i>Inquiry (United States)</i> , 2022 , 59, 469580221093171	1.4	